TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
施金元SHIH, JIN-YUAN
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
41筆
31
Liang, S. K., Ko, J. C., Yang, J. C. H., & Shih, J. Y. (2019). Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer, 133, 103-109. https://doi.org/10.1016/j.lungcan.2019.05.019
32
Lin, Y. T., Chen, J. S., Liao, W. Y., Ho, C. C., Hsu, C. L., Yang, C. Y., Chen, K. Y., Lee, J. H., Lin, Z. Z., Shih, J. Y., Yang, J. C. H., & Yu, C. J. (2019). Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. International Journal of Cancer, 144(11), 2887-2896. https://doi.org/10.1002/ijc.32025
33
Lin, Y. T., Liu, Y. N., & Shih, J. Y. (2019). The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer. Frontiers in Oncology, 9, Article 880. https://doi.org/10.3389/fonc.2019.00880
34
Liu, Y. N., Tsai, M. F., Wu, S. G., Chang, T. H., Tsai, T. H., Gow, C. H., Chang, Y. L., & Shih, J. Y. (2019). Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. International Journal of Cancer, 145(6), 1609-1624. https://doi.org/10.1002/ijc.32487
35
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Aix, S. P., Paz-Ares, L., Chiu, C. H., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J. Y., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., Reck, M., & Investigators, R. S. (2019). Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 20(12), 1655-1669. https://doi.org/10.1016/s1470-2045(19)30634-5
36
Weng, C. H., Chen, L. Y., Lin, Y. C., Shih, J. Y., Lin, Y. C., Tseng, R. Y., Chiu, A. C., Yeh, Y. H., Liu, C., Lin, Y. T., Fang, J. M., & Chen, C. C. (2019). Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene, 38(4), 455-468. https://doi.org/10.1038/s41388-018-0454-2
37
Wu, J. Y., Yu, C. J., & Shih, J. Y. (2019). Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 20(6), E620-E630. https://doi.org/10.1016/j.cllc.2019.06.018
38
Wu, S. G., Chang, T. H., Liu, Y. N., & Shih, J. Y. (2019). MicroRNA in Lung Cancer Metastasis. Cancers, 11(2), Article 265. https://doi.org/10.3390/cancers11020265
39
Wu, S. G., Chang, T. H., Tsai, M. F., Liu, Y. N., Hsu, C. L., Chang, Y. L., Yu, C. J., & Shih, J. Y. (2019). IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. Cancers, 11(1), Article 36. https://doi.org/10.3390/cancers11010036
40
Yang, C. Y., Hsieh, M. S., Liao, W. Y., Shih, J. Y., & Yu, C. J. (2019). Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma. Journal of Oncology Practice, 15(2), 115-+. https://doi.org/10.1200/jop.18.00536
